Interestingly, Park et al. studied the relationship between ABC transporter gene expression and chemotherapy responsiveness in early breast cancer patients who underwent sequential weekly paclitaxel/FEC (5-FU, epirubicin and cyclophosphamide) neoadjuvant therapy. This evidence concerns the gene ABCG2 and breast cancer.